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ABSTRACT: A rational molecular design strategy for tuning the emission color of phosphorescent complexes by functionalization 
of the bis-(2-phenylpyridine)(2-(2´-oxyphenyl)-2-oxazoline/oxazole)iridium(III) framework is reported. Five new complexes 2-6 
have been synthesized in good yields and characterized by cyclic voltammetry, absorption and photoluminescence studies, by time-
dependent density functional theory (TD-DFT) calculations, and single-crystal X-ray diffraction studies for complexes 2, 4 and 6. 
An interesting feature of the complexes is that the HOMO is localized on the Ir d-orbitals and the phenoxylate part of the ‘ancillary’ 
ligand, while the LUMO is located on the pyridyl ring of the ppy ligands. A few other complexes containing 2’-oxyphenyl-2-
oxazoline/oxazole ancillary ligands have been reported previously; however, until now there has not been a systematic investigation 
into manipulating this unusual frontier orbital distribution to tune the emissive properties. It is shown that exchanging the 
phenylpyridine (ppy) ligand for 2,4-difluoro-ppy gives a blue shift of 21-22 nm (from 1 to 2, and from 4 to 5) and the introduction 
of electron-withdrawing substituents  (SO2Me, CF3) onto the phenoxylate ring of the (2´-oxyphenyl)-2-oxazole ligand results in a 
further blue shift of 13-20 nm. Combining these functionalizations gives sky-blue emission with λmax
PL
 476 and 479 nm for com-
plexes 5 and 6 in dichloromethane solution. The solution quantum yields of all the complexes are within the range ΦPL 0.42-0.73. 
The observed lifetimes (τobs = 1.52-3.01 μs) and spectral profiles are indicative of phosphorescence from a mixture of ligand-
centered (LC) and MLCT excited states. (TD-)DFT calculations are in close agreement with the observed photophysical and elec-
trochemical properties of the complexes.  Phosphorescent organic light-emitting diodes (PhOLEDs) have been fabricated using 
complexes 2, 3, 5 and 6 as the emitter, doped in a 4,4-bis(N-carbazolyl)biphenyl (CBP) host, giving efficient emission in the blue-
green region. Notably, complex 5 gives λmax
EL
 480 nm with maximum brightness of 26150 cd m
-2
.  
INTRODUCTION  
Luminescent transition metal complexes1 are renowned for 
their applications in diverse areas such as biological probes,2 
responsive materials,3 water splitting, ion sensors, solar cells, 
phosphorescent organic light-emitting diodes (PhOLEDs) and 
solid-state lighting.  In the context of PhOLEDs4 and lighting5 
iridium(III) complexes have been at the forefront of attention 
since the pioneering studies of Forrest et al,6 due to their out-
standing combination of properties, namely: (i) synthetic ver-
satility, (ii) good stability and color-tunability, (iii) high phos-
phorescence quantum efficiency, (iv) relatively short excited-
state lifetimes of a few microseconds, and (v) good thin film 
processability. For these applications, homoleptic [Ir(C^N)3] 
and heteroleptic iridium(III) complexes [Ir(C^N)2L], are typi-
cally based on cyclometalated 2-phenylpyridine (ppy) ligands
  
 
Figure 1. Chemical structures of the oxazoline (1, 2) and 
oxazole complexes (3-6). 
 Scheme 1. Synthesis of ancillary ligands 11 and 12. Reagents 
and conditions: (i) aminoacetaldehyde diethylacetal, 160 
o
C, 
(ii) MeSO3H/P4O10, 180 
o
C, (iii) BBr3, 0 
o
C, DCM 
where the highest occupied molecular orbital (HOMO) is pri-
marily localized on the iridium d-orbitals and the phenyl ring, 
while the lowest unoccupied molecular orbital (LUMO) is 
predominantly located on the pyridyl ring.7 Emission is gener-
ally from a mixture of triplet metal-to-ligand charge-transfer 
(
3
MLCT) states and * transitions within the ligands. Elec-
tron-withdrawing groups on the phenyl ring of ppy lower the 
HOMO level while electron-donating groups on the pyridyl 
ring increase the LUMO level.8 Varying the ancillary ligand in 
heteroleptic complexes, e.g. L = acetylacetonate,9 picolinate,10 
bis(pyrazolyl)borate11 or  pyridylazolate,12 is also an estab-
lished strategy for color tuning of emission by perturbing the 
MLCT interaction. In some complexes interligand energy 
transfer can occur from the cyclometalating ppy ligand to the 
ancillary ligand, e.g. with a quinoline carboxylate ancillary 
ligand.13  
We recently reported that complex 1 (Figure 1) featuring a 2’-
oxyphenyl-2-oxazoline ancillary ligand showed promising 
green PhOLED performance, and, in particular, displayed an 
interesting distribution of the frontier orbitals.14 The LUMO of 
1 is located on the pyridyl ring of the ppy ligands, while the 
HOMO is localized on the Ir d-orbitals and the phenoxylate 
part of the ‘ancillary’ ligand.
14
 A few other complexes contain-
ing 2’-oxyphenyl-2-oxazoline/oxazole ancillary ligands have 
been reported.15  However, there is a lack of systematic inves-
tigation into manipulating this unusual frontier orbital distribu-
tion to tune the emissive properties.  
In this work we focus on the synthesis, photophysical and 
electrochemical properties of five new iridium(III) complexes 
2-6, each with an oxazoline or oxazole ancillary ligand. Our 
targets were designed to utilize the unusual HOMO-LUMO 
distribution to blue shift the emission relative to complex 1. 
We have successfully achieved this via simple and rational 
substitutions on both the phenylpyridine and the ancillary lig-
ands. It is well documented in the literature that introducing 
electron-withdrawing groups, such as fluorine,
11
 
perfluoroalkyl,16 sulfonyl,17
,18 phosphoryl,
17
 and cyano substit-
uents, onto positions of HOMO localization is an effective 
method to blue shift the emission of the resultant iridium com-
plex. With this in mind we introduced SO2Me and CF3 groups 
para to the hydroxyl on the 2-(2´-oxyphenyl)-2-oxazole ligand 
with the aim of lowering the HOMO. Fluorine substituents 
were also introduced on the ppy ligands, even though they 
have little contribution to the HOMO in 1, as it was thought 
they could blue-shift the emission by lowering the energy of 
the iridium d-orbitals, a strategy that is known for ancillary 
ligands.
10
 PhOLED fabrication and efficient device perfor-
mance in the blue-green region is reported for selected deriva-
tives.  
RESULTS AND DISCUSSION 
Synthesis 
 The syntheses of the ancillary oxazole-based ligands and their 
derived complexes are shown in Schemes 1-3. All the com-
plexes were characterized by NMR spectroscopy, mass spec-
trometry and elemental analysis, with X-ray crystal structures 
of complexes 2, 4 and 6. The synthesis of oxazoline ligand 21 
(Scheme 3) is described in the literature.
14,19 The  oxazole-
containing ligand 11 was synthesized as shown in Scheme 1, 
via a condensation between carboxylic acid 7 and 
aminoacetaldehyde diethylacetal, followed by in situ 
deprotection of the masked aldehyde 8 and oxazole formation 
with Eaton’s reagent. Two products were isolated, the desired 
compound 9, and the methanesulfonyl derivative 10 (ca. 1:1 
ratio). As we were interested in functionalizing the ancillary 
ligand, additional quantities of 10, along with analog 19, were 
synthesized as shown in Scheme 2, as it transpired that the 
route in Scheme 1 was not compatible with the desired sub-
stituents on the phenyl ring. The new route (Scheme 2) in-
volved a condensation reaction between carboxylic acids 13 
and 14 and aminoacetaldehyde diethylacetal to give 15 and 16. 
The next step was a deprotection of the masked aldehyde with 
HCl to give 17 and 18, followed by a cyclization with Bur-
gess’ reagent under microwave conditions,20 to give ligand 
precursors 10 and 19. The final step in both schemes was 
demethylation of 9, 10 and 19, which was achieved using ei-
ther BBr3 or pyridine.HCl, to afford the phenol derivatives 11, 
12 and 20, respectively.  
The new heteroleptic complexes 2-6 were then synthesized 
using standard conditions21 (Scheme 3). 
 
Scheme 2. Synthesis of ancillary ligands 12 and 20. Reagents 
and conditions: (i) 1) SOCl2, reflux, 2) aminoacetaldehyde 
diethylacetal, NEt3, DCM, RT, (ii) catalytic HCl, ace-
tone/water, reflux, (iii) Burgess’ reagent, THF, microwaves, 
70 
o
C, (iv) BBr3, 0 
o
C, DCM, (v) pyridine.HCl, 160 
o
C  
  
Scheme 3: Synthesis of complexes 2-6. Reagents and conditions: (i) IrCl3.3H2O, 2-ethoxyethanol, 130 
o
C (ii) ancillary ligand 11, 
12, 20 or 21, Na2CO3, 2-ethoxyethanol, 130 
o
C 
 
The intermediate μ-dichloro bridged dimer [Ir(L)2Cl]2 was 
reacted in situ with the appropriate ancillary ligand 11, 12, 20 
or 21 in the presence of Na2CO3. The complexes 2-6 were 
obtained as yellow powders in 57-87% yields. The NMR spec-
tra of 5 and 6 were obtained in acetone-d6. This was because 
upon  storage of  the solutions of 5 and 6 in CDCl3 under am-
bient conditions (laboratory light at 20 
o
C) partial re-formation 
of the dichloro bridged dimer was observed. This is ascribed 
to the presence of traces of acid, as noted by Baranoff et. al. 
for previous complexes.22  
 
Thermal, Photophysical and Electrochemical Properties 
The thermal stabilities of the iridium complexes were evalu-
ated using thermogravimetric analysis (TGA) under a nitrogen 
atmosphere. The 5% weight loss temperatures (Td) are above 
300 °C for all complexes, suggesting the complexes should be 
thermally stable under device operation (Table S2).  
The absorption and emission spectra of the complexes 2-6 in 
dichloromethane solutions are shown in Figure 2, and the data 
for 1-6 are listed in Table 1.  The strong bands between 250-
320 nm are assigned to π-π* transitions on the ligands based 
on literature precedents.23 Absorption bands in the range of 
350-460 nm with lower extinction coefficients are assigned to 
the 
1
MLCT/
3
MLCT bands following literature precedents,
18
 
and the calculations of Hay.24 Emission from the complexes is 
in the green/blue-green region, and the following trends are 
observed. (i) Exchanging the oxazoline of the parent complex 
1 for an oxazole (complex 3) results in a small blue shift of 6 
nm. This could be due to the increased electron withdrawing 
capability of the oxazole fragment, compared to the oxazoline, 
as a result of the extended conjugation.  
(ii) Exchanging the ppy ligand for 2,4-difluorophenylpyridine 
gives a blue shift of 21-22 nm (from 1 to 2, and from 4 to 5) 
although computational data (see below) suggests the HOMO 
is localized on the phenoxylate of the ancillary ligand, not the 
phenyl of ppy. This change of emission color can be explained 
by the presence of two fluorines that could still influence the 
energy levels of the iridium d-orbitals, which are heavily in-
volved in the excited state. 
(iii) The introduction of electron-withdrawing moieties 
(SO2Me, CF3) onto the phenoxylate ring of the ancillary ligand 
results in a further blue shift of 13-20 nm. This was expected 
as the HOMO in the complexes is localized on that ring (see 
below).  
(iv) The emission profiles of the complexes 2-4 is similar to 
that of the parent complex 1
14
, and are broad and largely fea-
tureless, indicating a strong MLCT contribution to the emis-
sion. However, for complexes 5 and 6 stronger vibronic fea-
tures are observed as the emission is shifted further towards 
the blue, suggesting an increase in the LC contribution to the 
emission.
23,24
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Figure 2. Absorption spectra of complexes 2-6 in DCM [<10
-5
 M]. Emission spectra of complexes 2-6 in degassed DCM [<10
-5
 M], 
λex = 355 nm.  
 
 
 Table 1. Photophysical data for iridium complexes 1-6. 
Complex λmax
abs (ε) / nm (×103 M-1 cm-1)a 
λmax
em / 
nmb 
PLQY / 
ΦPL
a,c 
τP / 
μsa,d 
kr /  
105 s-1 
knr / 10
5 
s-1 
Eox1/2  
/ V e 
HOMO 
/ eV f 
T1 / eV
h 
1
g 249, 340 (sh), 377 (sh), 443 (sh) 527 0.55 0.34 1.61 1.32 0.08 -4.88 2.51 
2 
252 (104.8), 275 (sh, 74.2), 334 
(18.7), 374 (16.0), 390 (14.7), 438 
(3.9), 464 (1.8) 
506 0.65 1.52 4.28 2.30 0.37 -5.17 2.49 
3 
255 (119.3), 280 (sh, 79.3), 303 
(sh, 43.3), 386 (20.8), 402 (18.5), 
456 (5.2), 488 (2.0) 
521 0.45 1.71 2.63 3.22 0.18 -4.98 2.57 
4 
253 (111.0), 279 (83.2), 297 
(64.1), 339 (18.9), 365 (18.3), 380 
(17.3), 401 (13.4), 451 (4.5), 483 
(1.2) 
508 0.42 1.80 2.33 3.22 0.30 -5.10 2.56 
5 
251 (118.6), 291 (65.5), 325 
(20.6), 379 (16.2), 429 (3.5), 457 
(1.4) 
476, 501 0.73 3.01 2.43 0.90 0.76 -5.56 2.71 
6 
248 (140.3), 275 (89.9), 329 
(20.3), 382 (20.7), 439 (2.6), 458 
(1.2) 
479, 502 0.69 2.95 2.34 1.05 0.72 -5.52 2.69 
a Data obtained in dichloromethane solution at 20 oC. b Data obtained in degassed dichloromethane solution with λex = 380 nm. 
c Measured 
in degassed DCM relative to  quinine sulfate ΦPL= 0.546 in 0.5 M H2SO4 at 20 
oC; estimated error ±5%. d Estimated error ±5%.e All values 
are reported vs Fc/Fc+ = 0.00 V. Measured in DCM (0.1 M nBu4NPF6) at 298 K. 
f  Obtained from the electrochemical oxidation potential. g 
Values for complex 1 taken from reference12. h Estimated from the onset wavelengths of the 77 K emission spectra measured in THF solu-
tion with λex = 365 nm (Figure S38).  
 
The photoluminescence quantum yields (PLQYs), lifetimes 
(τobs) and calculated radiative and non radiative decay rates (kr 
and knr) are stated in Table 1. QYs are in the range ΦPL 0.42-
0.73. The observed lifetimes (τobs = 1.52−3.01 μs) are indica-
tive of phosphorescence from a mixture of ligand-centered  
(LC) and MLCT excited states.6
b,25 
Electrochemistry 
The electrochemical behavior of the complexes was investi-
gated using cyclic voltammetry (CV) in a 
n
Bu4NPF6 dichloro-
methane solution. All the complexes show an electrochemical- 
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Figure 3. Cyclic voltammograms of complexes 2-6 measured 
in DCM (0.1 M 
n
Bu4NPF6) at 298 K. 
ly quasi/irreversible oxidation at 0.08-0.76 V vs Fc/Fc
+
, as-
signed to the Ir(III)/Ir(IV) couple (Table 1, Figure 3). Ex-
changing the ppy ligand for dfppy (1 to 2, and 4 to 5) results in 
a large increase in the oxidation potential, of 0.29-0.46 V, 
indicating the fluorine substituents are efficient at lowering the 
HOMO. Introducing electron-withdrawing groups on the 
phenoxylate ring also increases the oxidation potential, (by 
0.12 V for SO2Me; compare 3 and 4); this is consistent with 
the HOMO of 4 localized primarily on the phenoxylate ring of 
the ancillary ligand (see below) and introducing an electron-
withdrawing group, such as a sulfone, should lower the 
HOMO level. Upon replacing the oxazoline fragment with an 
oxazole (1 to 3) the oxidation potential increases by 0.1 V. As 
the HOMO for 1 is localized on the iridium d-orbitals and 
across the phenoxylate ring it is possible that switching from 
an oxazoline to an oxazole lowers the HOMO energy due to 
the increased electron withdrawing ability of the oxazole com-
pared to the oxazoline. If the LUMO energies are assumed to 
be very similar in these complexes, the relative HOMO ener-
gies from their CV data are consistent with the λmax values 
obtained from the emission spectra (Table 1). No reduction 
features were observed within the solvent window (scanning 
to -1.5 V vs Fc/Fc
+
).  
 
X-ray crystallography  
Single crystal structures were obtained for 2, 4 and 6. In each 
case the Ir atom has a distorted octahedral coordination (Fig 
 
  
Figure 4. X-ray molecular structures of complexes 2, 4 and 6. The DCM (2), THF (4) and DCM/chloroform (6) molecules of crystalli-
zation and the disorder of the CF3 group in 6 are not shown. Thermal ellipsoids are drawn at the 30% (2) or 50% (4, 6) probability level.
ure 4). The 2-(2’-oxyphenyl)-2-oxazoline/oxazole ligand is 
chelating the metal via its oxy and N atoms. In 2 the oxazoline 
ring is planar, as in the non-coordinated molecule 21 in the 
crystal.26 The twist between the oxazoline and benzene rings in 
2 is 8.1°, whereas in 21 it is practically nil; planarity of 21 is 
stabilized by an intramolecular  O-H…N bond. Nevertheless, 
the inter-ring bond C(2)-C(3) is shorter in 2 than in 21, 
1.442(6) vs 1.462(1) Å. The oxyphenyloxazole ligand in 4 and 
6 is more planar and shows a stronger -delocalisation in the 
chelate ring (Table 2). The C,N-chelating ppy ligands also 
show small but significant twists between the two aromatic 
systems. The Ir-C(11) bond, trans to the Ir-O(1), is shorter 
than the Ir-C(22) which is trans to the oxazole/oxazoline N(1), 
as expected from the trans-effect.  The nitrogen atoms of these 
ligands are trans to each other; interestingly, in all three com-
plexes the Ir-N(2) bond is slightly shorter than Ir-N(3), i.e. the 
Ir-N and Ir-C bonds in a chelate ring strengthen simultaneous-
ly.  
 
The crystal packing of 2 shows intermolecular stacking  
Table 2. Selected bond distances (Å) and interplanar angles 
(°) between mean ring planes 
a Bond distances averaged between two independent molecules. 
b Ring notation is shown in Fig. 4. 
between rigorously parallel rings iii and v and their respective 
inversion equivalents; the interplanar separations being 
iii/iii’3.57 and v/v’ 3.60 Å. This may result in a continuous 
chain of - interactions. In 6 there is also a continuous chain 
through intermolecular stacking of moieties iii and iv, which 
are only approximately parallel (interplanar angle 11.4°, aver-
age separation 3.44 Å). The molecules of 4 form no such chain 
but a dimer through a tight - contact between inversion-
related moieties v at 3.36 Å interplanar separation and 3.69 Å 
distance between ring centroids, which amounts to a 1.53 Å 
parallel slip of the rings along the N(3)…C(30) direction. 
 
 
Theoretical calculations 
Electronic structure calculations were performed on complex-
es 2, 4 and 6 to elucidate the nature of the transitions involved 
in the excitation spectra. The full geometries were optimized 
at the B3LYP/LANL2DZ:6-31G* level and are denoted 2’, 4’ 
and 6’ to distinguish them from experimental data. To assist in 
assigning the nature of the excited states involved in the exper-
imental absorption spectra, the singlet excited states were ob-
tained based on TD-DFT calculations. The frontier molecular 
orbitals of 2’, 4’ and 6’ are shown in Figures S1, 5 and S2 
respectively, while the transition character, orbital distribu-
tions and the simulated UV-Vis absorption spectra of the 
complexes, are summarized in Table 3. The computed orbital 
energies and energy gaps for 2’, 4’ and 6’ show good agree-
ment with the observed oxidation potentials and trends in pho-
toluminescence measurements (Table 1). All three complexes 
display similar frontier orbital distributions, with the LUMOs 
localized mostly on the phenylpyridine based ligands, while 
the HOMOs are spread across the iridium atom, and the 
phenoxylate ring of the ancillary ligand. It is noted that the 
HOMO of 4’ also has a significant contribution from the phe-
nyl rings of the ppy ligands.  
 
Electrophosphorescent device properties 
PhOLED devices of complexes 2, 3, 5 and 6 were fabricated 
in the following configuration: ITO/NPB (40 nm)/CBP:Ir 
complex(8%) (30 nm)/TPBi (25 nm)/LiF/Al. All the devices 
were fabricated by thermal evaporation onto a cleaned glass 
substrate pre-coated with conductive transparent indium tin 
oxide (ITO), where 4,4’-bis(N-(1-naphthyl)-N-
phenylamino)biphenyl (NPB) served as a hole-transporting 
layer (HTL) and 1,3,5-tris(N-phenylbenzimidazol-2-
yl)benzene (TPBi) as an electron-transporting layer (ETL) and 
  
 2 4 6a 21 
Ir-O(1) 2.134(3) 2.1452(8) 2.135(2)  
Ir-N(1) 2.119(3) 2.137(1) 2.126(2)  
Ir-N(2) 2.030(3) 2.035(1) 2.031(2)  
Ir-N(3) 2.040(4) 2.042(1) 2.041(2)  
Ir-C(11) 1.979(4) 1.989(1) 1.986(2)  
Ir-C(22) 2.001(4) 2.000(1) 2.001(2)  
N(1)-C(2) 1.292(6) 1.3116(15) 1.310(3) 1.283(1) 
C(2)-C(3) 1.442(6) 1.4477(16) 1.443(3) 1.462(1) 
C(3)-C(4) 1.415(6) 1.4333(16) 1.428(3) 1.410(1) 
O(1)-C(4) 1.293(5) 1.2890(14) 1.295(3) 1.354(1) 
C(2)-O(2) 1.351(5) 1.3544(14) 1.356(2) 1.348(1) 
i/iib 8.1 4.3 2.9, 3.5 0 
iii/iv 6.2 6.8 5.9, 2.5  
v/vi 4.5 3.1 13.7, 9.1  
 Table 3. TD-DFT calculation results for complexes 2’, 4’ and 6’. 
Complex 
Transition 
energya 
Participating MO Transition characterb 
Energy gap 
 / eV 
2’ 
452.3 nm HOMO→LUMO (96.8%) LCLACT+ MLACT 
3.35 439.3 nm HOMO→LUMO+1 (98.2%) LCLBCT+MLBCT+LCLACT 
376.0 nm HOMO→LUMO+2 (93.2%) LCLACT+LCLBCT+MLACT+MLBCT 
4’ 
441.4 nm HOMO→LUMO (94.9%) LCLBCT+ MLBCT+ LALBCT 
3.55 409.9 nm HOMO-1→LUMO (89.4%) LCLBCT+ MLBCT 
382.1 nm HOMO→LUMO+2 (97.2%) LBLCCT+MLCCT+LALCCT 
6’ 
421.07 nm 
HOMO→LUMO (81.6%) 
HOMO-1→LUMO (15.3%) 
LCLBCT+ MLBCT 
LCLBCT+ MLBCT+LALBCT 
3.62 
404.25 nm 
HOMO-1→LUMO (75.2%) 
HOMO→LUMO (12.8%) 
LCLBCT+ MLBCT+LALBCT 
LCLBCT+ MLBCT 
355.87 nm HOMO→LUMO+2 (93.2%) MLCCT +LBLCCT 
a
 Excitation energies calculated for the excited states. 
b 
Ligand notation: A, B =2-(2,4-difluorophenyl)pyridyl/2-phenylpyridyl; C =2 
-(2’-oxyphenyl)-2-oxazoline/4-(methylsulfonyl)-2-(oxazol-2-yl)phenol  
 
CBP (4,4’-bis(N-carbazolyl)-1,1’-biphenyl) is the host. The 
device structure and the corresponding energy level diagram 
of the respective active layers are shown in Figure 6a. Com-
plex 4 could not be sublimed, and so devices were not fabri-
cated.  The normalized electroluminescence (EL) spectra of 
the devices at 1000 cd m
-2
 (Figure 6b) are consistent with the 
photoluminescence (PL) spectra. The EL spectrum of each 
device 
 
Figure 5. The contour plots of the HOMOs and LUMOs of complex 4’. 
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Figure 6. a) Energy diagram of the devices. b) EL spectra of devices at a brightness of 1000 cd m−2. c) Current density-luminance-driving 
voltage curves of devices. d) EQE-luminance curves of devices. e) PE-luminance curves of devices. 
did not change substantially in the whole range of driving 
voltages, and no host emission was observed in the EL spectra, 
indicating good exciton confinement on the emissive mole-
cules.  Devices 2 and 3 showed the brightest emission in the 
greenish-blue (λmax
EL 
496 nm) and green (λmax
EL
 524 nm) re-
gions, respectively. This result indicates that introducing elec-
tron-withdrawing groups such as fluorine onto the 
cyclometalated (C^N) ligand indeed leads to the larger 
bandgap and the blue shifted emission. Furthermore, complex-
es 5 and 6 which have the same C^N ligand as 2, exhibited 
sky-blue emission (λmax
EL
 480 nm) in the corresponding devic-
es, indicating that the color of electroluminescence could be 
tuned also through rational structural variations of the ancil-
lary ligands. Here, it is worth noting that the CIE coordinates 
of devices 5 (0.22, 0.42) and 6 (0.17, 0.38) are very different 
from each other due to the relatively narrow full spectral width 
at half maximum (FWHM) of device 6 (Figure 6b), although 
they possess the same emission peak at max 480 nm. These 
data show that the device emission color can be optimized 
through adjusting the emission bandwidth,
14
 which here has 
been realized by introducing the different substituents  
(SO2Me or CF3) in the ancillary ligand.  
Figures 6c-e show the current density-voltage-luminance, ex-
ternal quantum efficiency and power efficiency-luminance 
 Table 4: Summary of device data. 
Device/ 
complex 
Maximum 
Brightness / cd m-2 
Turn-on voltagea  
/ V 
EQEb / % PEb / lm/W λELmax
 c
 / nm CIEx,y 
c  
1d 61560 3.5 17.7, 17.1, 14.2 47.2, 35.1, 20.8 530 (0.35, 0.61) 
2 28130 4.1 15.6, 14.5 11.3 28.5, 21.6, 12.7 496 (0.19, 0.53) 
3 28050 2.7 17.3, 14.8, 11.3 52.5, 37.2, 25.5 524 (0.33, 0.61) 
5 26150 4.5 2.6, 3.3, 3.5 5.1, 5.3, 4.5 480 (0.22, 0.42) 
6 9670 4.6 2.8, 3.1, 2.6 4.1, 3.5, 2.5 480 (0.17, 0.38) 
a 
Measured at the brightness of 1 cd m
-2
. 
b 
Values at the brightness of 10, 100 and 1000 cd  m
-2
 respectively. 
c 
Values at a brightness of 1000 cd m
-2
.
 
d 
data taken from ref. 14. 
 
characteristics of the devices 2, 3, 5 and 6. All the devices 
exhibited a low turn-on voltage (recorded at 1 cd m
−2
) and the 
EL intensity rises rapidly  after the onset voltages. The corre-
sponding maximum luminance values were obtained at rather 
low voltages as listed in Table 4. Device 3 exhibited compara-
ble EL efficiency, with the reference device 1 based on the 
similar green emission,
14
 while the other devices exhibited 
higher driving voltages and lower EL efficiencies attributed to 
the blue shift in emission compared with devices 1 and 3. This 
is consistent with the known trend of reduced efficiency upon 
blue-shifting the emission in this spectral region.
27
 These de-
vices generally realized high efficiencies and insignificant 
efficiency roll-off. Both the EQE and PE values of these de-
vices maintained high levels at luminance values of 10, 100 
and 1,000 cd m
-2
. Such stable and high EL performance based 
on the simple device structure suggests that the effective 
charge transport and recombination exists throughout these 
devices. Notably, devices 2, 3 and 5 reached maximum 
brightnesses of >26000 cd m
-2
.  
 
CONCLUSIONS 
The new complexes 2-6 have been rationally designed and 
synthesized, and their optoelectronic and structural properties 
have been characterized, along with their applications as emit-
ters in PhOLEDs. The emission color of photoluminescence 
and electroluminescence has been tuned via systematic func-
tionalization of both the cyclometalating ligand and the ancil-
lary ligand, which contribute significantly to the frontier or-
bital distributions. Exchanging the phenylpyridine (ppy) lig-
and for 2,4-difluoro-ppy gives a blue shift of 21-22 nm (from 
1 to 2, and from 4 to 5) and the introduction of electron-
withdrawing substituents  (SO2Me, CF3) onto the phenoxylate 
ring of the (2´-oxyphenyl)-2-oxazole ligand results in a further 
blue shift of 13-20 nm. Combining these functionalizations 
gives λmax
PL
 476 and 479 for complexes 5 and 6 in dichloro-
methane solution with PLQYs of ca 0.7. (TD-)DFT calcula-
tions are in excellent agreement with the observed 
photophysical and electrochemical properties of the complex-
es.   PhOLEDs fabricated from the complexes generally 
demonstrated high efficiencies and very limited efficiency 
roll-off. Both the EQE and PE values maintained high levels at 
luminance values of 10, 100 and 1000 cd m
-2
, with devices 2, 
3 and 5 achieving maximum brightnesses of >26000 cd m
-2
. 
Our rational molecular design strategy for tuning the emission 
color has exploited the unusual frontier orbital distribution in 
these complexes, namely a significant HOMO character on the 
phenoxylate part of the ancillary ligand. Functionalization of 
an ancillary ligand, as developed in this work, is an attractive 
complementary approach to the more usual methodology of 
design and synthesis of different (C^N) cyclometalating lig-
ands, where complex formation can be synthetically more 
challenging for steric and electronic reasons.   
  
EXPERIMENTAL DATA  
General procedures 
All commercially available chemicals were used without further puri-
fication. Reactions requiring an inert atmosphere were performed 
under a blanket of argon gas, which was dried over a phosphorus 
pentoxide column. Anhydrous solvents were dried through an HPLC 
column on an Innovative Technology Inc. solvent purification system.  
Column chromatography was performed using 40-60 μm mesh silica 
gel. Analytical TLC was performed on plates pre-coated with silica 
gel (Merck, silica gel 60F254) and visualized using UV light (254, 315, 
365 nm). NMR spectra were recorded on Bruker Avance 400 MHz, 
Varian Mercury 200, and 400 MHz, Varian Inova 500 MHz or Varian 
VNMRS 600 and 700 MHz spectrometers. Chemical shifts are refer-
enced to tetramethylsilane [TMS, Si(CH3)4] at 0.00 ppm. Melting 
points were determined in open ended capillaries using a Stuart Scien-
tific SMP3 melting point apparatus at a ramping rate of 1 
o
C/min. 
They are recorded to the nearest 0.1 
o
C. ESI and MALDI mass spectra 
were recorded on a Thermo-Finnigan LTQ FT (7.0 T magnet) spec-
trometer. ASAP mass spectra were recorded on a Waters Xevo QTOF 
spectrometer. GCMS spectra were recorded on a Thermo-Finnigan 
Trace GCMS (EI and CI ion sources). Elemental analyses were ob-
tained on an Exeter Analytical Inc. CE-440 elemental analyzer. Mi-
crowave reactions were conducted in a sealed vessel in a Biotage 
Initiator microwave synthesizer (0-400 W). Where solvent mixtures 
are mentioned any percentage/ratio is by volume. 
Electrochemistry 
Cyclic voltammetry (CV) data were obtained using a BAS CV50W 
electrochemical analyzer fitted with a three-electrode system consist-
ing of a Pt disk (Ø = 1.8 mm) as the working electrode, a Pt wire as an 
auxiliary electrode and an additional platinum wire as the reference 
electrode.  The experiments were conducted in dry DCM solution 
with 
n
Bu4NPF6 (0.1 M) as the supporting electrolyte at a scan rate of 
100 mV/s. The data were internally referenced to 
decamethylferrocene, which was then referenced to Fc/Fc
+
 to allow 
comparison with the literature and estimation of the HOMO levels.   
Solution photophysics 
Solution state photophysical data were obtained using freshly 
prepared solutions of the complexes in the solvent specified. Emission 
and lifetime measurements were taken using thoroughly degassed 
solutions achieved by three freeze−pump−thaw cycles, and obtained 
using a quartz cuvette with a path length of 1 cm. The solutions had 
absorbance below 0.10 to minimize inner filter effects. All UV-vis 
 absorption measurements were recorded using a Unicam UV2-100 
spectrometer operated with the Unicam Vision(ver. 3.50) software. 
Baseline correction was achieved by reference to pure solvent in the 
same cuvette. Absorption measurements were obtained using quartz 
cuvettes with a path length of 2 cm. Solution PLQYs were recorded in 
degassed solvent, and determined using the relative method, with 
quinine sulfate (ΦPL = 0.546 in 0.5 M H2SO4) as the reference. The 
PLQYs were computed according to the following equation: 
        
     
       
  
  
    
 
 
 
where subscripts ‘x’ and ‘ref’ denote the material being measured and 
the reference, respectively. Φ represents the PLQY, Grad is the gradi-
ent of the gradient from the plot of integrated fluorescence intensity 
vs absorbance, and η is the refractive index of the solvent. Excitation 
and emission photoluminescence spectra were recorded on a Horiba 
Jobin Yvon SPEX Fluorolog 3-22 spectrofluorometer. Quantum 
yields were determined in degassed DCM in comparison with a 
standard [quinine sulfate = 0.546 in 0.5 M H2SO4]. Solutions of the 
complexes in degassed DCM [<10
-5
 M] were used for decay 
measurements. The sample was excited by the output of a pulse laser 
diode which produced a 1 kHz train of pulses of 20 ns duration at 405 
nm.  The luminescence was collected at 90° and focused onto the 
entrance slit of a monochromator (Bethan TM 300V).  The emission 
was detected by a photon counting photomultiplier tube and the arri-
val times of photons at the detector were determined using a mult i-
channel scaler.  
X-ray crystallography 
X-ray diffraction experiments for 4 and 6 were carried out on a 
Bruker 3-circle CCD diffractometer D8 Venture with a PHOTON 100 
CMOS area detector, using Mo-Kα radiation from a IμS microsource 
with focussing mirrors and a Cryostream (Oxford Cryosystems) open-
flow N2 gas cryostat. For 2, the experiment was carried out at room 
temperature on a Bruker Smart Apex II CCD diffractometer, using 
Mo-Kα radiation (λ = 0.71069 Å). Structure 4 was solved by Patterson 
methods, 6 by direct methods using SHELXS 2013/1 software
28
 and 2 
by direct methods using SIR2002 software.
29
 The structures were 
refined in anisotropic approximation by full matrix least squares 
against F
2
 off all data, using OLEX2
30
 and SHELXL 2014/7 soft-
ware.
31
  The asymmetric unit of 4 contains one complex molecule and 
two molecules of THF, one of them partly disordered. The asymmet-
ric unit of 6 contains two complex molecules (both with rotationally 
disordered CF3 groups) and one disordered solvent molecule. Presum-
ably, the latter site is shared by DCM and CDCl3 molecules in a 
0.8:0.2 ratio. The asymmetric unit of 2 contains one complex mole-
cule and half of one DCM molecule, the latter having crystallographic 
C2 symmetry. 
Thermal Analysis 
Thermogravimetric analysis (TGA) was performed in a nitrogen at-
mosphere using a Perkin-Elmer Pyris 1 TGA instrument. The com-
plexes were heated at a rate of 10 
o
C /min from room temperature up 
to 600 
o
C. 
Synthesis and Characterization 
Iridium complex 2 
IrCl3.3H2O (209 mg, 0.59 mmol) was added to a stirred solution of 2-
(2,4-difluorophenyl)pyridine (250 mg, 1.31 mmol) in 2-ethoxyethanol 
(6 mL) under argon. The solution was heated to 135 
o
C for 6 h, before 
2-(2’-hydroxyphenyl)-2-oxazoline 21
14,19
 (121 mg, 0.74 mmol) and 
Na2CO3 (315 mg, 2.97 mmol) were added and the solution was heated 
at 135 
o
C overnight. Water was added and the yellow precipitate was 
collected by filtration. The residue was purified by column 
chromatography (hexane:EtOAc 4:1) to give complex 2 as a yellow 
solid (310 mg, 79%); Anal. Calc. for C31H20F4IrN3O2: C, 50.68; H, 
2.74; N, 5.72. Found: C, 50.43; H, 3.07; N, 5.47; δH (400 MHz; 
CD2Cl2) 8.78 (1H, d, J 5.2), 8.39 (1H, d, J 5.8), 8.26 (2H, t, J 8.9), 
7.87 – 7.75 (2H, m), 7.61 (1H, d, J 8.1), 7.21 (1H, t, J 6.6), 7.14 (2H, 
t, J 7.0), 6.60 (1H, d, J 8.7), 6.45 – 6.32 (3H, m), 5.79 (1H, dd, J 8.9, 
2.3), 5.62 (1H, dd, J 8.9, 2.4), 4.36 (1H, q, J 9.3), 4.23 (1H, q, J 8.5), 
3.64 – 3.47 (1H, m), 3.14 – 3.00 (1H, m); δF (376 MHz CD2Cl2;) -
109.30 (1F, q, J 9.1), -109.34 (1F, q, J 9.3), -110.90 (1F, ddd, J 12.4, 
10.1, 1.6), -110.95 (1F, ddd, J 12.5, 10.1, 2.5); HRMS (FTMS+ESI): 
calcd for [C31H20F4N3O2Ir+H]+: 734.1176. Found: 734.1186. Crystals 
for X-ray analysis were grown by slow evaporation of a 
DCM/methanol solution of 2. 
 
N-(2,2-diethoxyethyl)-2-methoxybenzamide 8 
Methyl-2-methoxybenzoate 7 (5.00 g, 28.93 mmol) and 
aminoacetaldehyde diethylacetal (2.78 g, 17.25 mmol) were com-
bined and the mixture was heated to 160 
o
C for 4 h before being 
cooled to RT. An NMR spectrum of the crude material showed the 
reaction had not gone to completion; more aminoacetaldehyde 
diethylacetal (1.00 g, 6.20 mmol) was added and the reaction was 
heated to 160 
o
C overnight before being cooled to RT. Any methanol 
produced was removed by rotary evaporation and the oily residue was 
purified by column chromatography (hexane:EtOAc 1:1) to give an 
oil, N-(2,2-diethoxyethyl)-2-methoxybenzamide 8 (2.80 g, 36%); δH 
(400 MHz; CDCl3) 8.21 (1H, dd, J 7.8, 1.9), 8.15 (1H, br t, J 5.5), 
7.45 (1H, ddd, J 8.3, 7.3, 1.8), 7.08 (1H, ddd, J 7.8, 7.3 1.0), 6.98 
(1H, dd, J 8.4, 1.0), 4.63 (1H, t, J 5.6), 3.97 (3H, s), 3.76 (dq, J 9.4, 
7.0), 3.67 – 3.54 (4H, m), 1.25 (6H, t, J 7.0); HRMS (FTMS+ESI): 
calcd for [C14H21NO4+Na]+: 290.1368. Found: 290.1368. The 
13
C 
NMR spectrum could not be obtained as 8 hydrolyzed to the aldehyde 
in the NMR solvent; δH (600 MHz; CDCl3) 9.76 (1H, d, J 0.6), 8.64 
(1H, br s), 8.21 (1H, dd, J 7.7, 1.9), 7.51 – 7.45 (1H, m), 7.09 (1H, t, J 
7.6), 7.01 (1H, d, J 8.4), 4.41 (2H, dd, J 4.8, 0.7), 4.03 (3H, d, J 0.6); 
δC (151 MHz; CDCl3) 196.97, 165.69, 157.96, 133.45, 132.52, 
121.48, 120.70, 111.55, 56.20, 51.15.   
 
2-(2-methoxyphenyl)oxazole 9 and 2-(2-methoxy-5-
(methylsulfonyl)phenyl)oxazole 10 
Methanesulfonic acid (35 mL) was added cautiously to N-(2,2-
diethoxyethyl)-2-methoxybenzamide 8 (2.80 g, 11.70 mmol) with 
stirring. P4O10 (4.50 g, 15.85 mmol) was added with caution and the 
mixture was heated to 180 
o
C overnight. The mixture was cooled to 
RT and added dropwise to aq. NaHCO3 solution (300 mL) with stir-
ring. The aqueous phase (pH 8) was extracted with DCM (3 × 400 
mL) and the solvent was removed in vacuo to leave a thick oil. The 
residue was purified by column chromatography (10-20% EtOAc in 
DCM) to give the product 9 as a yellow oil (400 mg, 19%); δH (400 
MHz; CDCl3) 7.98 (1H, dd, J 8.1, 1.8), 7.76 (1H, d, J 0.8), 7.46 (1H, 
ddd, J 8.3, 7.4, 1.8), 7.31 (1H, d, J 0.8), 7.04- 7.11 (2H, m), 4.00 (3H, 
s); δC (151 MHz; CDCl3) 160.44, 157.67, 138.31, 131.90, 130.41, 
128.28, 120.79, 116.61, 112.10, 56.20; HRMS (FTMS+ESI): calcd 
for [C10H9NO2+H]
+
: 176.0712. Found: 176.0740. 
Also isolated was a second fraction: 2-(2-methoxy-5-
(methylsulfonyl)phenyl)oxazole 10 (538 mg, 18%); δH (400 MHz; 
CDCl3) 8.54 (1H, dd, J 2.4, 0.8), 8.01 (1H, ddd, J 8.8, 2.4, 0.8), 7.78 
(1H, d, J 0.8), 7.33 (1H, s), 7.18 (1H, d, J 8.8), 4.07 (3H, s), 3.09 (3H, 
s); δC (151 MHz; CDCl3) 161.29, 158.31*, 139.10, 131.21, 130.18, 
128.69, 117.36*, 112.49, 56.85, 44.94, (* denotes carbons identified 
from the HMBC spectrum). One carbon is not observed due to low 
solubility; HRMS (FTMS+ESI): calcd for [C11H11NO4S+H]
+
: 
254.0487. Found: 254.0471. 
 
2-(oxazol-2-yl)phenol 11 
BBr3 (0.65 ml, 6.87 mmol) was added dropwise to a stirred solution 
of 2-(2-methoxyphenyl)oxazole 9 (400 mg, 2.28 mmol) in DCM (10 
mL, dry) over an ice bath. The suspension was stirred at RT overnight 
before the reaction was quenched with water (CAUTION). The solid 
formed, presumed to be (2-(2-hydroxyphenyl)oxazol-3-ium bromide) 
was filtered off and suspended in DCM. This was then washed with 
aq. Na2CO3 to neutralize the salt. The organic phase was collected and 
the aqueous phase was washed with further DCM (3 × 50 mL). The 
organic phases were combined, dried over MgSO4 and filtered. The 
solvent was removed in vacuo to give an oil, 2-(oxazol-2-yl)phenol 11 
(250 mg, 68%); δH (700 MHz; CDCl3) 11.20 (1H, s), 7.84 (1H, dd, J 
7.8, 1.7), 7.69 (1H, t, J 0.9), 7.39 – 7.34 (1H, m), 7.24 (1H, d, J 1.0), 
7.08 (1H, dd, J 8.3, 1.2), 6.95 (1H, td, J 7.5, 1.0); δC (176 MHz; 
CDCl3) 161.78, 157.35, 137.49, 132.47, 126.51, 126.08, 119.52, 
 117.31, 111.25; HRMS (FTMS+ESI): calcd for [C9H7NO2+H]
+
: 
162.0555. Found: 162.0542. 
 
4-(methylsulfonyl)-2-(oxazol-2-yl)phenol 12 
BBr3 (0.61 mL, 6.37 mmol) was added dropwise to a stirred solution 
of 2-(2-methoxy-5-(methylsulfonyl)phenyl)oxazole 10  (538 mg, 
mmol) in DCM (10 mL, dry) over an ice bath. The suspension was 
stirred at RT overnight before the reaction was quenched with water 
(CAUTION). The solid formed, presumed to be 2-(2-hydroxy-5-
(methylsulfonyl)phenyl)oxazol-3-ium bromide, was filtered off and 
suspended in DCM. This was then washed with aq. Na2CO3 to neu-
tralize the salt. The organic phase was collected and the aqueous 
phase was washed with further DCM (3 × 50 mL). The organic phases 
were combined, dried over MgSO4 and filtered. TLC revealed a mix-
ture of starting material and product; the crude mixture was redis-
solved in DCM and extracted with aq. NaOH solution (3 × 50 mL, 1 
M). The aqueous phases were combined, acidified to pH 6 with conc. 
HCl and re-extracted with DCM (4 × 100 mL). The organic phase was 
dried over MgSO4, the solvent was removed and the residue was 
purified by silica plug (EtOAc) to give a white solid, 4-
(methylsulfonyl)-2-(oxazol-2-yl)phenol 12 (200 mg, 39%) which was 
recrystallized from methanol. δH (400 MHz; CDCl3) 11.91 (1H, s), 
8.47 (1H, d, J 2.4), 7.91 (1H, dd, J 8.8, 2.4), 7.79 (1H, d, J 0.9), 7.32 
(1H, d, J 0.9), 7.23 (1H, d, 8.8), 3.10 (3H, s); δC (101 MHz; CDCl3) 
161.39, 160.21, 138.54, 131.68, 131.30, 126.78, 126.56, 118.56, 
111.65, 45.01; HRMS (FTMS+ESI): calcd for [C10H9NO4S]
+
: 
240.0331. Found: 240.0335. 
 
Iridium complex 3 
IrCl3.3H2O (123 mg, 0.35 mmol) 
was added to a stirred solution of 
2-phenylpyridine (0.11 mL, 0.77 
mmol) in 2-ethoxyethanol (10 mL). 
The solution was heated to reflux 
(135 
o
C) overnight. Na2CO3 (300 
mg, 2.83 mmol) and 2-(oxazol-2-
yl)phenol 11 (62 mg, 0.38 mmol) 
were added and the solution was 
heated to reflux overnight before 
being cooled to RT. Water was 
added and the precipitate was fil-
tered to give a yellow solid. The crude product was filtered and 
washed with more water to remove water-soluble impurities. The 
product was dried, then washed with hexane and cold diethyl ether to 
remove traces of ppy ligand. The product was obtained as a yellow 
solid, 3 (200 mg, 87%); Anal. Calc. for C31H22IrN3O2.0.25CH2Cl2: C, 
55.00; H, 3.33; N, 6.17. Found: C, 55.18; H, 3.26; N, 6.02; δH (700 
MHz; CDCl3) 8.88 (1H, d, J 5.7, HA6), 7.99 (1H, d, J 5.8, HC6), 7.85 
(1H, d, J 8.2, HC3), 7.80 (1H, d, J 8.2, HA3), 7.72 (1H, dd, J 8.2, 1.9, 
HF3), 7.67 (1H, td, J 8.1, 1.5, HA4), 7.65 (1H, td, J 8.1, 1.5, HC4), 7.59 
(1H, dd, J 7.9, 1.1, HD3), 7.56 (1H, dd, J 7.6, 1.1, HB3), 7.38 (1H, d, J 
1.0, HE2), 7.12 (1H, ddd, J 8.7, 7.0, 1.9, HF5), 7.07 (1H, ddd, J 7.4, 
6.0, 1.4, HA5), 6.92 (1H, ddd, J 8.1, 5.9, 1.4, HC5), 6.87 (1H, td, J  7.5, 
1.2, HD4), 6.86 (1H, td, J 7.4, 1.2, HB4), 6.80 – 6.75 (2H, m, HF6+D5), 
6.73 (1H, dt, J 7.3, 1.1, HB5), 6.42 (1H, ddd, J 7.9, 6.9, 1.1, HF4), 6.36 
(1H, d, J 7.6, HB6), 6.28 (1H, d, J 7.6, HD6), 6.20 (1H, d, J 1.0, HE1); 
δC (151 MHz; CDCl3) 169.22 (CC2), 168.10 (CA2), 167.20 (CF1), 
158.67 (CE3), 152.67 (CD1), 149.07 (CA6) 148. 72 (CB1), 148.67 (CC6), 
144.87 (CB2), 144.83 (CD2), 137.49 (CE2), 136.91 (CA4), 136.74 (CC4),  
133.20 (CB6), 132.56 (CF5), 132.48 (CD6), 129.69 (CB5), 129.58 (CD5), 
127.39 (CF3), 126.64 (CE1), 125.53 (CF6), 124.18 (CB3), 124.10 (CD3), 
122.07 (CA5) 121.80 (CC5), 120.79 (CD4), 119.02 (CB4), 118.73 (CC3), 
118.25 (CA3), 113.34 (CF4), 110.94 (CF2); HRMS (FTMS+ESI): calcd 
for [C31H22N3O4
191
Ir+H]
+
: 660.1396. Found: 660.1406. 
 
Iridium complex 4 
IrCl3.3H2O (236 mg, 0.67 mmol) was added to a stirred solution of 2-
phenylpyridine (0.21 mL, 1.47 mmol) in 2-ethoxyethanol (10 mL). 
The solution was heated to reflux (135 
o
C) overnight. Na2CO3 (354 
mg, 3.34 mmol) and 4-(methylsulfonyl)-2-(oxazol-2-yl)phenol 12 
(200 mg, 0.84 mmol) were added and the solution was heated to re-
flux overnight before being cooled to RT. Water was added and the 
precipitate was filtered to give a yellow solid. The crude material was 
purified by column chromatography (10% EtOAc in DCM) to give 
the product as a yellow solid. Fractions containing product 4 contami-
nated with unreacted ppy were combined, the solvent was then re-
moved and the solid was washed with hexane to give additional prod-
uct 4 (combined yield: 281 mg, 57%); Anal. Calc. for C32H24IrN3O4S: 
C, 52.02; H, 3.27; N, 5.69. Found: C, 51.84; H, 3.61; N, 5.27; δH (400 
MHz; CDCl3) 8.75 (1H, ddd, J 5.8, 1.5, 0.7), 8.38 (1H, d, J 2.6), 7.96 
(1H, d, J 5.7, 1.5, 0.7), 7.91 (1H, d, J 8.1), 7.87 (1H, d, J 8.1), 7.75 
(1H, td, J 7.6, 1.7), 7.73 (1H, td, J 7.5, 1.6), 7.60 (1H, td, J 8.4, 1.1), 
7.57 (1H, dd, J 9.2, 2.6), 7.49 (1H, d, J 1.0), 7.14 (1H, ddd, J 7.3, 5.7, 
1.4), 7.01 (1H, ddd, J 7.4, 5.8, 1.5), 6.93 (1H, td, J 7.5, 1.2), 6.92 (1H, 
td, J 7.5, 1.2), 6.82 (1H, d, J 9.2), 6.79 (1H, td, J 6.16, 1.2), 6.76 (1H, 
td, J 7.4, 1.4), 6.83 – 6.77 (1H, m), 6.79 – 6.74 (m, 1H), 6.38 (1H, dd, 
J 7.7, 1.0), 6.29 (1H, dd, J 7.6, 1.0), 6.27 (1H, d, J 1.0), 3.04 (s, 3H); 
HRMS (FTMS+ESI): calcd for [C32H24N3O4S
191
Ir]
+
: 737.1094. 
Found: 737.1118. Crystals for X-ray analysis were grown by slow 
evaporation of a solution of 4 in tetrahydrofuran. 
 
N-(2,2-diethoxyethyl)-2-methoxy-5-(methylsulfonyl)-benzamide 
15 
SOCl2 (15 mL) was added to 2-methoxy-5-(methylsulfonyl)benzoic 
acid 13 (6.00 g, 26.06 mmol) and the mixture was heated to reflux 
under a nitrogen atmosphere for 3 h, before being cooled to RT. The 
excess SOCl2 was removed in vacuo to leave an off-white solid, 2-
methoxy-5-(methylsulfonyl)benzoyl chloride, which was used with-
out further purification. A solution of 2-methoxy-5-
(methylsulfonyl)benzoyl chloride in DCM (20 mL) was added 
dropwise to a stirred solution of aminoacetaldehyde diethylacetal 
(4.16 mL, 28.66 mmol), NEt3 (0.33 mL, 28.66 mmol) in DCM (40 
mL). The reaction was left to stir at RT overnight. The solvent was 
removed in vacuo, and solid was then suspended in water and 
sonicated, followed by stirring. The product was then collected via 
filtration. This washing was repeated a second time, and the product 
was collected as a white solid, N-(2,2-diethoxyethyl)-2-methoxy-5-
(methylsulfonyl)-benzamide 15 (7.25 g, 81%); δH (400 MHz; CDCl3) 
8.77 (1H, d, J 2.6), 8.04 (1H, dd, J 8.7, 2.6), 7.94 (1H, s), 7.13 (1H, d, 
J 8.8), 4.63 (1H, t, J 5.4), 4.07 (3H, s), 3.76 (2H, dq, J 9.4, 7.1), 3.67 
– 3.53 (4H, m), 3.06 (3H, s), 1.25 (6H, t, J 7.0); δC (101 MHz; CDCl3) 
163.49, 161.14, 133.64, 132.39, 132.09, 122.90, 112.13, 100.86, 
63.02, 56.77, 44.66, 42.60, 15.53; the molecular ion was not observed 
and the product was characterized by fragment ions, MS (ASAP+): 
[M-OEt]
+
 = 300.1 [M-NHCH2CH(OEt)2]
+
 = 213.0. 
 
N-(2,2-diethoxyethyl)-2-methoxy-5-trifluoromethyl-benzamide 16 
SOCl2 (7 mL) was added to 2-methoxy-5-(trifluoromethyl)benzoic 
acid 14 (1.37 g, 6.22 mmol) and the mixture was heated to reflux 
under a nitrogen atmosphere for 3 h, before being cooled to RT. The 
excess SOCl2 was removed in vacuo to leave an off-white solid, 2-
methoxy-5-trifluoromethylbenzoyl chloride, which was used without 
further purification. A solution of 2-methoxy-5-
trifluoromethylbenzoyl chloride in DCM (5 mL) was added dropwise 
to a stirred solution of aminoacetaldehyde diethylacetal (1.00 mL, 
6.84 mmol), NEt3 (0.95 ml, 6.84 mmol) in DCM (20 mL). The reac-
tion was stirred at RT overnight, before the solvent was removed in 
vacuo. The resulting solid was then suspended in water and sonicated, 
followed by stirring. The product was then collected via filtration. 
This was repeated a second time, and the product was collected as a 
white solid, N-(2,2-diethoxyethyl)-2-methoxy-5-trifluoromethyl-
benzamide 16 (2.00 g, 97%); δH (400 MHz; CDCl3) 8.51 (1H, d, J 
2.5), 8.04 (1H, br s), 7.70 (1H, ddd, J 8.7, 2.6, 0.8), 7.07 (1H, d, J 
8.7), 4.63 (1H, t, J 5.4), 4.03 (3H, s), 3.76 (2H, dq, J 9.4, 7.0), 3.67 – 
3.53 (4H, m), 1.25 (6H, t, J 7.0); δF (376 MHz; CDCl3) -61.89 (3F, d, 
J 0.8); δC (101 MHz; CDCl3) 164.06, 159.77, 130.16 (q, J 3.8), 
129.83 (q, J 3.8), 124.08 (q, J 272.1), 123.96 (q, J 32.3), 122.10, 
111.76, 100.99, 63.01, 56.48, 42.58, 15.54; HRMS (FTMS+ESI): 
calcd for [C15H20F3NO4+Na]
+
: 358.1242. Found: 358.1245. 
 
2-methoxy-5-(methylsulfonyl)-N-(2-oxoethyl)benzamide 17 
 Dilute HCl (2 drops, 2 M) was added to a stirred solution of N-(2,2-
diethoxyethyl)-2-methoxy-5-(methylsulfonyl)-benzamide 15 (2.00 g, 
5.79 mmol) in acetone/water (60 mL/20 mL) and the mixture was 
heated to reflux  for 5 h before stirring at RT overnight. The solvent 
was removed in vacuo to give the product, 2-methoxy-5-
(methylsulfonyl)-N-(2-oxoethyl)benzamide 17 (1.57 g, 100%); δH 
(400 MHz; CDCl3) 9.78 (1H, s), 8.77 (1H, d, J 2.5), 8.49 (1H, br s), 
8.07 (1H, dd, J 8.8, 2.5), 7.17 (1H, d, J 8.8), 4.46 (2H, d, J 4.7), 4.14 
(3H, s), 3.07 (3H, s); δC (101 MHz; CDCl3) 196.11, 163.56, 161.37, 
133.77, 132.57, 132.53, 122.04, 112.30, 57.00, 51.28, 44.70; HRMS 
(FTMS+ESI): calcd for [C11H13NO5S+H]
+
: 272.0593. Found: 
272.0606. 
 
2-methoxy-N-(2-oxoethyl)-5-(trifluoromethyl)benzamide 18 
HCl (2 drops, 2M) was added to a stirred solution of N-(2,2-
diethoxyethyl)-2-methoxy-5-trifluoromethyl-benzamide 16 (2.00 g, 
5.96 mmol) in acetone/water (30 mL/10 mL), and the mixture was 
heated to reflux  for 4 h before being stirred at RT overnight. The 
solvent was removed in vacuo to give the product, 2-methoxy-N-(2-
oxoethyl)-5-(trifluoromethyl)benzamide 18 (1.56 g, 100%.); δH (400 
MHz; CDCl3) 9.78 (1H, s), 8.57 (1H, br s), 8.51 (1H, d, J 2.4), 7.73 
(1H, ddd, J 8.7, 2.5, 0.8), 7.11 (1H, d, J 8.7), 4.45 (2H, d, J 4.7), 4.10 
(3H, s); δF (376 MHz; CDCl3) -61.92 (3F, s); δC (176 MHz; CDCl3) 
196.3, 164.17, 160.00 (d, J 0.9), 130.31 (q, J 3.8), 130.21 (q, J 3.8), 
124.04 (q, J 32.1), 124.03 (q, J 271.6), 121.23, 111.90, 56.69, 51.25; 
HRMS (FTMS+ESI): calcd for [C11H10NO3F3+H]
+
: 262.0691. Found: 
262.0693 
 
2-(2-methoxy-5-(methylsulfonyl)phenyl)oxazole 10 
Burgess’ reagent (2.07 g, 8.69 mmol) was added to a solution of 2 -
methoxy-5-(methylsulfonyl)-N-(2-oxoethyl)benzamide 17 (1.57 g, 
5.79 mmol) in THF (15 mL) in a 20 mL microwave vial. The reaction 
was heated to 70 
o
C in the microwave for 10 min with stirring. Once 
cooled, the solvent was removed and the residue purified by column 
chromatography (EtOAc) to give the product, 2-(2-methoxy-5-
(methylsulfonyl)phenyl)oxazole 10 (0.30 g, 20%); NMR data were 
consistent with the sample obtained previously (see above). 
 
Iridium complex 5 
IrCl3.3H2O (120 mg, 0.34 mmol) was added to a solution of dfppy 
(143 mg, 0.75 mmol) in 2-ethoxyethanol (5 mL) and the mixture was 
heated to 130 
o
C overnight under a nitrogen atmosphere. The mixture 
was cooled, and Na2CO3 (180 mg, 1.70 mmol) and 4-
(methylsulfonyl)-2-(oxazol-2-yl)phenol 12 (102 mg, 0.43 mmol) were 
added. The solution was heated to reflux overnight under a nitrogen 
atmosphere, before being cooled to RT, and the solvent removed in 
vacuo. The residue was purified by column chromatography (hex-
ane:acetone 2:1). The solid obtained was dissolved in methanol, and 
triturated with hexane to give the product as a yellow solid (197 mg, 
71%); Anal. Calc. for C32H20IrN3O4F4S: C, 47.40; H, 2.49; N, 5.18. 
Found: C, 47.00; H, 2.56; N, 5.07; δH (400 MHz; Acetone-d6) 8.76 
(1H, ddd, J 5.8, 1.7, 0.8), 8.36 – 8.26 (4H, m), 8.09 – 7.97 (3H, m), 
7.56 (1H, dd, J 9.1, 2.6), 7.44 (1H, ddd, J 7.4, 5.8, 1.4), 7.28 (1H, 
ddd, J 7.4, 5.8, 1.5), 6.68 (1H, d, J 9.1), 6.60 (1H, ddd, J 12.8, 9.4, 
2.4), 6.56 (1H, ddd, J 12.8, 9.4, 2.4), 6.46 (1H, d, J 1.1), 5.84 (1H, dd, 
J 8.8, 2.4), 5.67 (1H, dd, J 8.9, 2.4), 3.03 (3H, s); δF (376 MHz; Ace-
tone-d6) -109.37 (1F, q, J 9.4), -110.28 (1F, q, J 9.5), -111.32 (1F, t, J 
11.5), -112.06 (1F, t, J 11.3); HRMS (FTMS+ESI): calcd for 
[C32H20N3O4F4S
191
Ir+H]
+
: 810.0795. Found: 810.0803. 
 
2-(2-methoxy-5-(trifluoromethyl)phenyl)oxazole 19 
Burgess’ reagent (0.43 g, 1.80 mmol) was added to a solution of 2-
methoxy-N-(2-oxoethyl)-5-(trifluoromethyl)benzamide 18 (0.24 g, 
0.92 mmol) in THF (4 mL) in a 2-5 mL microwave vial. Five vials 
were set up, and the reactions were heated to 70 
o
C in the microwave 
for 10 min with stirring. Once cooled, the solutions were combined 
and the solvent was removed. The residue was purified by column 
chromatography (initially DCM, changed to 10% EtOAc in DCM) to 
give the product, 2-(2-methoxy-5-(trifluoromethyl)phenyl)oxazole 19 
(440 mg, 40%); δH (400 MHz; CDCl3) 8.24 (1H, d, J 2.4), 7.77 (1H, 
d, J 0.8), 7.68 (1H, ddd, J 8.8, 2.5, 0.8), 7.32 (1H, d, J 0.8), 7.12 (1H, 
d, J 8.8), 4.03 (3H, s); δF (376 MHz; CDCl3) -61.80 (3F, d, J 0.8); δC 
(101 MHz; CDCl3) 159.77, 159.13, 138.85, 128.76 (q, J 3.8), 128.62, 
127.79 (q, J 3.8), 124.11 (q, J 271.0), 123.23 (q, J 33.1), 117.00, 
112.14, 56.54; HRMS (FTMS+ESI): calcd for [C11H8NO2F3+H]
+
: 
244.0585. Found: 244.0580. 
 
4-(trifluoromethyl)-2-(oxazol-2-yl)phenol 20 
2-(2-Methoxy-5-(trifluoromethyl)phenyl)oxazole 19 (440 mg, 1.81 
mmol) was added to a molten pyridine hydrochloride (8.00 g, 69.22 
mmol) at 160 
o
C. The reaction was heated at 160 
o
C for 6 h before 
being cooled to RT. Water (40 mL) and EtOAc (40 mL) were added, 
and the layers were separated. The organic layer was washed with 
further water (3 × 50 mL), then dried over MgSO4 and the solvent 
removed in vacuo. The residue was purified by column chromatog-
raphy (DCM) to give a mixture of the product, 4-(trifluoromethyl)-2-
(oxazol-2-yl)phenol 20 and a decomposition product (102 mg). 20; δH 
(400 MHz; CDCl3) 11.60 (1H, s), 8.15 (1H, d, J 2.0), 7.78 (1H, d, J 
0.9), 7.62 (1H, ddd, J 8.7, 2.3, 0.7), 7.32 (1H, d, J 0.9), 7.18 (1H, d, J 
8.6); δF (376 MHz; CDCl3) -62.01 (3F, s); HRMS (FTMS+ESI): calcd 
for [C10H6NO2F3+H]
+
: 230.0429. Found: 230.0423. 
The decomposition product was identified by NMR and mass spec-
trometry as 2-hydroxy-5-(trifluoromethyl)-benzamide. 
 
Iridium complex 6 
IrCl3.3H2O (170 mg, 0.41 mmol) was added to a solution of dfppy 
(170 mg, 0.89 mmol) in 2-ethoxyethanol (5 mL) and the mixture was 
heated to 130 
o
C overnight under a nitrogen atmosphere. The mixture 
was cooled, and Na2CO3 (214 mg, 2.02 mmol) and 2-(2-methoxy-5-
(trifluoromethyl)phenyl)oxazole 20 (102 mg, 0.45 mmol) were added. 
The solution was heated to reflux overnight under a nitrogen atmos-
phere, before being cooled to RT, and the solvent removed in vacuo. 
The residue was purified by column chromatography (hexane:EtOAc 
2:1) to give the product as a yellow solid, complex 6 (160 mg, 50%); 
Anal. Calc. for C32H17IrN3O2F7: C, 48.00; H, 2.14; N, 5.25. Found: C, 
48.53; H, 2.31; N, 5.18; δH (400 MHz; Acetone-d6) 8.79 (1H, ddd, J 
5.7, 1.7, 0.8), 8.36 – 8.26 (3 H, m), 8.09 – 7.96 (4H, m), 7.43 (1H, 
ddd, J 7.3, 5.8, 1.4), 7.35 (1H, dd, J 9.1, 2.6), 7.27 (1H, ddd, J 7.4, 
5.8, 1.5), 6.69 (1H, d, J 8.9), 6.57 (2H, dddd, J 18.7, 12.8, 9.4, 2.4), 
6.44 (1H, d, J 1.1), 5.85 (1H, dd, J 8.8, 2.4), 5.67 (1H, dd, J 8.8, 2.4), 
2.81 – 2.75 (2H, m), 2.09 (3H, s); δF (376 MHz; Acetone-d6) -61.42 
(3F, m), -109.45 (1F, q, J 9.4), -110.37 (1F, q, J 9.4), -111.38 (1F, t, J 
11.5), -112.14 (1F, ddd, J 12.4, 9.9, 1.7); HRMS (FTMS+ESI): calcd 
for [C32H17N3O2F7
191
Ir+H]
+
: 800.0893. Found: 800.0883. Crystals for 
X-ray analysis were grown by slow evaporation of a 
DCM/CDCl3/hexane solution of 6 in an NMR tube. 
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Calculated orbital contour plots for complexes 2’ and 6’ 
 
Figure S1. The contour plots of the HOMOs and LUMOs of complex 2’. 
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Figure S2. The contour plots of the HOMOs and LUMOs of complex 6’. 
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X-ray crystallography  
Table S1. Crystal data 
Compound  2  4  6  
CCDC  1512945 1512946 1512947 
Formula  C31H20F4IrN3O2 
·½ CH2Cl2 
C32H24IrN3O4S 
·2C4H8O 
C32H17F7IrN3O2·0.4 
CH2Cl2·0.1 CHCl3 
Dcalc./ g cm
-3
  1.879  1.655  1.947  
μ/mm-1  5.02  3.88  4.81  
Formula Weight  777.16  883.01  846.59  
Size/mm
3
  0.23×0.21×0.18  0.22×0.21×0.20  0.29×0.21×0.19  
T/K  293  120  120  
Crystal System  monoclinic  monoclinic  triclinic  
Space Group  C2/c  P21/n  P-1  
a/Å  24.3108(14)  12.8946(5)  13.0961(6)  
b/Å  15.9429(14)  16.5103(7)  14.9991(7)  
c/Å  14.7716(10)  16.7577(7)  17.6182(9)  
α/°  90  90  100.939(2)  
β/°  106.302(2)  96.473(1)  105.983(2)  
γ/°  90  90  112.871(2)  
V/Å
3
  5495.1(7)  3544.9(3)  2888.2(2)  
Z  8  4  4  
Wavelength/Å  0.71073  0.71073  0.71073  
Θmax/
°
  25.082  35.607  35.800  
Measured Refls.  15352  96252  79318  
Independent Refls.  4876  15430  24074  
Refls. with I>2σ(I)  3983  13645  19800  
Rint  0.035  0.027  0.028  
Parameters/restraints  384, 0  467, 12  892, 46 
wR2 (all data)  0.066  0.037  0.054  
R1 [I>2σ(I)] 0.026  0.018  0.026  
 
Thermal properties 
Table S2. Thermal stability data for complexes 2-6. 
Complex Td (
oC)a 
2 308 
3 320 
4 310 
5 311 
6 304 
 a 
Defined as the 5% weight loss temperature. 
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Copies of NMR spectra  
 
 
Figure S3. 
1
H NMR spectrum of 2 in CD2Cl2. 
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Figure S4. 
19
F NMR spectrum of 2 in CD2Cl2. 
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Figure S5. 
1
H NMR spectrum of 3 in CDCl3. 
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 Figure S6. 
1
H NMR spectrum of 4 in CDCl3. 
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Figure S7. 
1
H NMR spectrum of 5 in Acetone-d6. 
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Figure S8. 
19
F NMR spectrum of 5 in Acetone-d6. 
 
S11 
 
S11 
 
 
Figure S9. 
1
H NMR spectrum of 6 in Acetone-d6. 
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Figure S10. 
19
F NMR spectrum of 6 in Acetone-d6. 
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Figure S11. 
1
H NMR spectrum of 8 in CDCl3. 
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 Figure S12. 
13
C NMR spectrum of 8 in CDCl3. 
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Figure S13. 
1
H NMR spectrum of 9 in CDCl3. 
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Figure S14. 
13
C NMR spectrum of 9 in CDCl3. 
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 Figure S15. 
1
H NMR spectrum of 10 in CDCl3. 
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Figure S16. 
13
C NMR spectrum of 10 in CDCl3. Due to the low intensity of the 
13
C spectrum the 2D 
NMR experiments have been included. 
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Figure S17. HSQC NMR spectrum of 10 in CDCl3. 
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Figure S18. HMBC NMR spectrum of 10 in CDCl3. 
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Figure S19. 
1
H NMR spectrum of 11 in CDCl3. 
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Figure S20. 
13
C NMR spectrum of 11 in CDCl3. 
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Figure S21. 
1
H NMR spectrum of 12 in CDCl3. 
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Figure S22. 
13
C NMR spectrum of 12 in CDCl3. 
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Figure S23. 
1
H NMR spectrum of 15 in CDCl3. 
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Figure S24. 
13
C NMR spectrum of 15 in CDCl3. 
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Figure S25. 
1
H NMR spectrum of 16 in CDCl3. 
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Figure S26. 
19
F NMR spectrum of 16 in CDCl3. 
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Figure S27. 
13
C NMR spectrum of 16 in CDCl3. 
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Figure S28. 
1
H NMR spectrum of 17 in CDCl3. 
 
 
 
S31 
 
S31 
 
 
Figure S29. 
13
C NMR spectrum of 17 in CDCl3. 
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Figure S30. 
1
H NMR spectrum of 18 in CDCl3. 
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Figure S31. 
19
F NMR spectrum of 18 in CDCl3. 
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Figure S32. 
13
C NMR spectrum of 18 in CDCl3. 
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Figure S33. 
1
H NMR spectrum of 19 in CDCl3. 
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Figure S34. 
19
F NMR spectrum of 19 in CDCl3. 
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Figure S35. 
13
C NMR spectrum of 19 in CDCl3. 
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Figure S36. 
1
H NMR spectrum of 20 in CDCl3. The * denotes peaks from the decomposition product. 
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Figure S37. 
19
F NMR spectrum of 20 in CDCl3. The * denotes peaks from the decomposition product. 
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Photophysical properties  
 
Figure S38. Emission spectra of complexes 2-6 at 77 K in THF solution with λex = 365 nm. 
